Apixaban conferred lower bleeding risk during a 3-month period compared with rivaroxaban in patients with acute venous thromboembolism, researchers reported.Despite higher medication adherence to ...

Patients with atrial fibrillation who use diltiazem combined with apixaban or rivaroxaban face an increased risk for serious bleeding events compared with those who use metoprolol.

For patients with prostate cancer, concurrent use of enzalutamide, apalutamide, or abiraterone with DOACs does not increase risks for thrombosis or bleeding.

Concomitant use of SSRIs and OACs was associated with a 33% increased risk for major bleeding. Among patients with atrial fibrillation (AF), concomitant use of selective serotonin reuptake inhibitors ...

If the novel factor XI inhibitor abelacimab reaches the market for patients with atrial fibrillation (AF) who require anticoagulation, it may not be necessary to interrupt treatment ahead of invasive ...

The researchers found that the event rates for any bleeding per 100 person-years were 3.5 and 6.3 during periods without and with NSAID use, respectively. (HealthDay News) — Patients with venous ...

In the CKD population treated with oral anticoagulants for atrial fibrillation, major bleeding is more likely in male patients and those with congestive heart failure, vascular disease, and a history ...

Lower risk for bleeding without increase in ischemic events seen for patients with acute coronary syndrome. HealthDay News — For patients with acute coronary syndrome (ACS) undergoing drug-eluting ...